Capecitabine for the treatment of pancreatic cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7‐30.
   Web of Science ®Google Scholar
• Russo S, Saif MW. 2016 gastrointestinal cancers symposium: update on pancreatic cancer. Ann Gastroenterol. 2016 Apr-Jun;29(2):238–240.
   PubMed Web of Science ®Google Scholar
• Abrams MJ, Rakszawski K, Vasekar M, et al. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American society of clinical oncology. Therap Adv Gastroenterol. 2016 Mar;9(2):141–151.
   PubMed Web of Science ®Google Scholar
• Passero FC Jr, Saif MW. Advancements in the management of pancreatic cancer: 2015 ASCO gastrointestinal cancers symposium (San Francisco, CA, USA. January 15-17, 2015). JOP. 2015 Mar 20;16(2):99–103.
   PubMed Web of Science ®Google Scholar
• Grapsa D, Saif MW, Syrigos K. Targeted therapies for pancreatic adenocarcinoma: where do we stand, how far can we go? World J Gastrointest Oncol. 2015 Oct 15;7(10):172–177.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605–3610.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617–3622.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):18.
   Web of Science ®Google Scholar
• Saif MW, Chabot J. Chemotherapy: metastatic pancreatic cancer–is FOLFIRINOX the new standard? Nat Rev Clin Oncol. 2011 Jul 5;8(8):452–453.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548–4554.
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. Oncology. 2014;32(2423):29.
   Google Scholar
• Gill S, Ko YJ, Cripps C, et al. PANCREOX: A randomized phase iii study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016 Nov 10;34(32):3914–3920.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. NAPOLI-1 study group.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545–557.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55(7):1091–1097.
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–1281.
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291.
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Inoue Y, Nagashima N, et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res. 2005;25(6A):3755–3761.
   PubMed Web of Science ®Google Scholar
• Judson I, Beale P, Trigo J, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of asingle oral dose of 14C-labelled drug. Invest New Drugs. 1999;17:49–56.
   PubMed Web of Science ®Google Scholar
• Reigner B, Clive S, Cassidy J, et al. Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43:309–315.
   PubMed Web of Science ®Google Scholar
• Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5:1696–1702.
   PubMed Web of Science ®Google Scholar
• Saadati H, Saif MW. Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function. JOP. 2008 May 8;9(3):354–356.
   PubMedGoogle Scholar
• Saif MW, Tejani MA. Safety of capecitabine use in patients with liver dysfunction. Clin Adv Hematol Oncol. 2007 Sep;5(9):730–732. discussion 736.
   PubMedGoogle Scholar
• Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002;49:225–234.
   PubMed Web of Science ®Google Scholar
• Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008 Jun;19(5):447–464.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011–1024. Epub 2017 Jan 25.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–1081.
   PubMed Web of Science ®Google Scholar
• Abrams MJ, Huber KE, Knisely JP, et al. Capecitabine as a radiosensitizer in adjuvant chemoradiotherapy for pancreatic cancer: a retrospective study. Anticancer Res. 2015 Dec;35(12):6901–6907.
   PubMed Web of Science ®Google Scholar
• Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern cooperative oncology group study. J Clin Oncol. 1985;3:373–378.
   PubMed Web of Science ®Google Scholar
• Saif MW, Hasmi S, Zelterman D, et al. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. Int J Colorectal Dis. 2008;23(2):139–145.
   PubMed Web of Science ®Google Scholar
• Saif MW, Joseph M, Tang S, et al. Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. J Appl Res. 2004;4(4):635–646.
   PubMedGoogle Scholar
• Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773–8781.
   PubMed Web of Science ®Google Scholar
• Saif MW, Eloubeidi MA, Russo S, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol. 2005 Dec 1;23(34):8679–8687.
   PubMed Web of Science ®Google Scholar
• Saif MW, Black G, Roy S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007 Jul-Aug;13(4):247–256.
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib. the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–1853.
   PubMed Web of Science ®Google Scholar
• Saif MW, Ledbetter L, Kaley K, et al. Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncol Lett. 2014 Sep;8(3):1302–1306. Epub 2014 Jun 11.
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002 Jan 1;20(1):160–164.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Schüll B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003 Jan;14(1):97–104.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the swiss group for clinical cancer research and the central European cooperative oncology group. J clin oncol. 2007;25(16):2212–2217.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–5518.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008 Mar 28;8: 82.
   PubMed Web of Science ®Google Scholar
• Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010 Mar;17(3–4):161–169.
   PubMed Web of Science ®Google Scholar
• Saif MW, Li J, Lamb L, et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014;73(2):373–380.
   PubMed Web of Science ®Google Scholar
• Kaori F, Yanagisawa M, Sekiguchi F, et al. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol. 2006;57:693–702.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25(30):4787–4792.
   PubMed Web of Science ®Google Scholar
• Chen J, Kaley K, Garcon MC, et al. A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Therap Adv Gastroenterol. 2016 Mar;9(2):162–168.
   PubMed Web of Science ®Google Scholar
• Lopez R, Méndez C, Fernández M, et al. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). Anticancer Res. 2013;33:717–723.
   PubMed Web of Science ®Google Scholar
• Ma W, Herman J, Jimeno A, et al. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010;3:373–379.
   PubMed Web of Science ®Google Scholar
• Fine R, Moorer G, Sherman W, et al. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol. 2009;27(15 Suppl.):Abstract4623.
   Google Scholar
• Benavides M, Plazas JG, Guillen C, et al. Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): efficacy and safety results of a phase IIb randomized study from the Spanish TTD collaborative group. J Clin Oncol. 2014;32(suppl):5s,abstr 4122.
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061–2067.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101–105.
   PubMed Web of Science ®Google Scholar
• Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2ʹ-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29–34.
   PubMed Web of Science ®Google Scholar
• Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther. 2009 Feb;18(2):29–41.
   Google Scholar
• Saif MW, Juneja V, Black G, et al. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther. 2007 Sep 1;4(4):211–218. .
   PubMedGoogle Scholar
• Kruger S, Boeck S, Heinemann V, et al. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. Acta Oncol. 2015 Jul;54(7):993–1000.
   PubMed Web of Science ®Google Scholar
• Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005 Jul;5(2):89–100.
   PubMedGoogle Scholar
• Saif MW. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2008. JOP. 2008 Jul 10;9(4):403–407.
   PubMedGoogle Scholar
• Shah HR, Ledbetter L, Diasio R, et al. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer. 2006 Jan;5(5):354–358.
   PubMed Web of Science ®Google Scholar
• Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005 Sep;5(3):175–180.
   PubMedGoogle Scholar
• Howell SB, Wung WE, Taetle R, et al. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer. 1981 Sep 15;48(6):1281–1289.
   PubMed Web of Science ®Google Scholar
• Harvey VJ, Slevin ML, Dilloway MR, et al. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984 Sep;18(3):421–430.
   PubMed Web of Science ®Google Scholar
• Kanamitsu SI, Ito K, Okuda H, et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl) uracil. Drug Metab Dispos. 2000 Apr;28(4):467–474.
   PubMed Web of Science ®Google Scholar
• Wakisaka S, Shimauchi M, Kaji Y, et al. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi. 1990 Apr;81(4):192–196.
   PubMedGoogle Scholar